Leadership

American Academy of Neurology
American Association of Neuromuscular and Electrodianostic Medicine
National Ataxia Foundation
Epilepsy Foundation of Louisiana Physician Advisory Board Member
American Red Cross Disaster Action Team Member

Publications

1. Vera-Ramirez, M., Charlet, M., Parry, G.J. - Recurrent Aspect Meningitis Complicating Intravenous lmmunoglobulin Therapy for chronic Inflammatory Demyelinating Polyradiculoneuropathy. Neurology August 1992; 42: 1636-1637. 

2. Switching from Immediate-Release to Extended-Release Carbamazepine Capsules: Safety and Tolerability in Adolescents with Epilepsy. Michael Charlet MD, Leonard J. Chabert Medical Center, Houma, LA, USA Presented at the American Epilepsy Society; December 3-7, 2004; New Orleans, LA. 

3. Switching to Carbamazeipine Extended Release Capsules from Immediate Release Formulations: Evaluation of Safety and Tolerability in Patients with Epilepsy. Michael Charlet MD, Leonard J. Chabert Medical Center, Houma, LA, USA Presented at the American Academy of Neurology; April 9-16, 2004; Miami, FL. 

4. Transitioning from Immediate-Release to Extended-Release Carbamazepine: Safety and Tolerability in Patients with Epilepsy. Michael Charlet MD, Leonard J. Chabert Medical Center, Houma, LA, USA Presented at the Joint Annual Meeting of the American Epilepsy Society and the American Clinical Neurophysiology Society; December 2-6, 2005; Washington DC. 

Research

Co-investigator of "A Double-Blind, Parallel, Placebo Controlled, Multiple Dose, 6-month Study Assessing the Safety and Efficacy of Daily Subcutaneous Injections of Recombinant Human Ciliary Neurotrophic Factor (rhCNTF) in Patients with Amyotrophic Lateral Sclerosis (ALS) 

SPEQT (Safety, Preference, Effectiveness, Quality of Life, and Tolerability) 
A multicenter, open-labeled, phase 4 study to assess the tolerability, safety, and effectiveness of changing treatment from carbamazepine immediate-release to carbatrol extended-release capsules in epilepsy subjects within a community-based population. Michael Charlet-PI 

Co-investigator of WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction). A randomized, double blind, multi-center clinical trial to determine whether warfarin or aspirin is superior for preventing mortality and stroke combined in patients with ejection fraction less than 30%, when balanced against any risk of intracerebral hemorrhage.

Principal Investigator in Eisai Clinical Study Protocol: E2007-G000-304. Study Title: A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures 

POLES- An open-label extension phase of the double-blind, placebo-controlled, dose­escalation, parallel-group study to evaluate the efficacy and safety of E2007 
(Perampanel) given as adjunctive therapy in subjects with refractory partial seizures; Sponsor: Eisai Medical Research; Pl-Dr. Michael Charlet; SI-Christine Thistlethwaite 

VERSA (VIMPAT EFFICACY RESPONSE AND SAFETY AS FIRST ADD-ON) AN OPEN-LABEL, MULTICENER, MULTINATIONAL STUDY OF LACOSAMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL­ONSET SEIZURES 
Pl-Dr. Michael Charlet; I - Christine Thistlethwaite; Sponsor - Schwarz Biosciences, lnc./UCB; CRO-Parexel Clinical Research 

LADS (LYRICA ANTI-EPILEPTIC DRUG STUDY) A DOUBLE-BLIND, RANDOMIZED, MUL TICENTER EFFICACY AND SAFETY STUDY OF PREGABLIN (L YRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES 
Pl- Dr. Michael Charlet, SI - Christine Thistlethwaite; Sponsor-Pfizer 

LOPES (L YRICA OPEN-LABEL EXTENSION STUDY) AN OPEN-LABEL 
MUL TICENTER EXTENSION STUDY TO DETERMINE LONG TERM SAFETY AND EFFICACY OF PREGABABLIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES 
Pl-Dr. Michael Charlet; SI-Christine Thistlethwaite; Sponsor-Pfizer 

CARBS Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients with Epilepsy; Pl- Dr. Michael Charlet, SI - Christine Thistlethwaite Sponsor: Lundbeck Inc.  Pfizer study A0081194(PRADA): "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Pregabalin Controlled Release Formulation as Adjunctive Therapy in Adults with Partial Onset Seizures" Pl- Dr. Michael Charlet